{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:25:09Z","timestamp":1746339909086},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","transplantation-proceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.transproceed.2014.02.023","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T14:44:31Z","timestamp":1402929871000},"page":"1531-1535","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modified Busulfan and Cyclophosphamide Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Patients With Hematologic Malignancies"],"prefix":"10.1016","volume":"46","author":[{"given":"X.F.","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.Y.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2014.02.023_bib1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2014.02.023_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00007890-198909000-00021","article-title":"Increasing utilization of bone marrow transplantation: II. Results of the 1985-1987 survey","volume":"48","author":"Bortin","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2014.02.023_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib4","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood.V92.9.3098","article-title":"Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease","volume":"92","author":"Greinix","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2014.02.023_bib5","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V95.4.1188.004k38_1188_1194","article-title":"Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age","volume":"95","author":"Deeg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2014.02.023_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/shem.2002.30909","article-title":"Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes","volume":"39","author":"Giralt","year":"2002","journal-title":"Semin Hematol"},{"key":"10.1016\/j.transproceed.2014.02.023_bib7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/bmt.2010.197","article-title":"Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility","volume":"46","author":"Wang","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bbmt.2013.04.005","article-title":"Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes","volume":"19","author":"Rezvani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bbmt.2009.07.014","article-title":"Busulfan and cyclophosphamide (Bu\/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience","volume":"15","author":"Ulrickson","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","article-title":"Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality","volume":"13","author":"McCune","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/petr.12061","article-title":"Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan\/cyclophosphamide conditioning","volume":"17","author":"M\u00e5rtensson","year":"2013","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2014.02.023_bib13","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2014.02.023_bib14","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0360-3016(81)90032-8","article-title":"Idiopathic interstitial pneumonia following bone marrow transplantation: the relationship with total body irradiation","volume":"7","author":"Keane","year":"1981","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.transproceed.2014.02.023_bib15","first-page":"64","article-title":"Comparsion of two conditioning regimens in allogeneic boen marrow transplantation","volume":"17","author":"Jie","year":"1996","journal-title":"Chinese J Hematol"},{"key":"10.1016\/j.transproceed.2014.02.023_bib16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone marrow transplantation (second of the two part)","volume":"292","author":"Thomas","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2014.02.023_bib17","first-page":"411","article-title":"The role of mesechymal stem cells in hematopoietic stem cells transplantation","volume":"26","author":"Shi","year":"2005","journal-title":"Chinese J Organ Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib18","first-page":"892","article-title":"Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility","volume":"46","author":"Wang","year":"2010","journal-title":"Chinese J Organ Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib19","first-page":"620","article-title":"Comparison of two condition regiment in treatment of leukemia by allogeneic hematopoietic stem cell transplantation","volume":"22","author":"GuoCai","year":"2003","journal-title":"Chinese J Cancer"},{"key":"10.1016\/j.transproceed.2014.02.023_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for iv BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/hep.510240414","article-title":"Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation","volume":"24","author":"DeLeve","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2014.02.023_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.bmt.1705034","article-title":"Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"36","author":"Huang","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib23","first-page":"1438","article-title":"Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"91","author":"de Lavallade","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.transproceed.2014.02.023_bib24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/sj.bmt.1702055","article-title":"Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD","volume":"24","author":"Bertz","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/sj.bmt.1705922","article-title":"Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children","volume":"41","author":"Inagaki","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2014.02.023_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.transproceed.2014.02.023_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000028359","article-title":"Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes","volume":"60","author":"DeLeve","year":"2000","journal-title":"Pharmacology"},{"key":"10.1016\/j.transproceed.2014.02.023_bib28","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134514001523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134514001523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:58:01Z","timestamp":1597971481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134514001523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0041134514001523"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.02.023","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modified Busulfan and Cyclophosphamide Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Patients With Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}